Internship

QV Automation Intern

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

East Side, PA, USA

Must be able to relocate to the office location and work 40 hrs./week for the full duration of the internship.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Currently pursuing a bachelor's degree in life sciences, engineering, or otherwise relevant technical area with the expectation that you will complete your current degree by the Spring of 2028
  • Must be enrolled in school the semester following your internship/co-op with Sanofi.
  • Must be able to relocate to the office location and work 40 hrs./week for the full duration of the internship/Co-op
  • Must have permanent US work authorization
  • Exceptional organizational, speaking, and writing capabilities.
Responsibilities
  • Supporting various projects and tasks related to vaccine production, from a site quality organization perspective.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi differentiates itself from competitors by its strong commitment to scientific innovation and a diverse product portfolio that includes prescription medicines and vaccines. Its goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for tolebrutinib boosts Sanofi's neurology portfolio.
  • Dupixent's EU approval expands Sanofi's pediatric treatment offerings.
  • Sanofi's investment in Zucara Therapeutics strengthens its diabetes treatment pipeline.

What critics are saying

  • Liver enzyme elevations in tolebrutinib trials may lead to regulatory scrutiny.
  • Competition in multiple sclerosis market could impact tolebrutinib's market share.
  • AI tools like Muse may face challenges from stringent data privacy regulations.

What makes Sanofi unique

  • Sanofi's partnership with BrightInsight enhances digital health solutions for specialty therapies.
  • Tolebrutinib is the first brain-penetrant BTK inhibitor for multiple sclerosis.
  • Sanofi's Muse AI tool optimizes patient recruitment in clinical trials.

Help us improve and share your feedback! Did you find this helpful?